MX2022011583A - Dpp3 en pacientes infectados con coronavirus. - Google Patents

Dpp3 en pacientes infectados con coronavirus.

Info

Publication number
MX2022011583A
MX2022011583A MX2022011583A MX2022011583A MX2022011583A MX 2022011583 A MX2022011583 A MX 2022011583A MX 2022011583 A MX2022011583 A MX 2022011583A MX 2022011583 A MX2022011583 A MX 2022011583A MX 2022011583 A MX2022011583 A MX 2022011583A
Authority
MX
Mexico
Prior art keywords
dpp3
level
therapy
correlating
determined
Prior art date
Application number
MX2022011583A
Other languages
English (en)
Inventor
Andreas Bergmann
Original Assignee
4TEEN4 Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP20179763.6A external-priority patent/EP3922993A1/en
Application filed by 4TEEN4 Pharmaceuticals GmbH filed Critical 4TEEN4 Pharmaceuticals GmbH
Publication of MX2022011583A publication Critical patent/MX2022011583A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La materia objeto de la presente invención es un método para (a) diagnosticar o predecir el riesgo de deterioro potencialmente mortal o un evento adverso o (b) diagnosticar o pronosticar la gravedad de o (c) predecir o monitorear el éxito de una terapia o intervención o (d) guía de la terapia o estratificación de la terapia o (e) manejo del paciente en un paciente infectado con un coronavirus, el método comprende: determinar el nivel de dipeptidil peptidasa 3 (DPP3) en una muestra de fluido corporal del paciente, comparar el nivel de DPP3 determinada a un umbral predeterminado, y correlacionar el nivel de DPP3 determinada con el riesgo de deterioro potencialmente mortal o un evento adverso, o correlacionar el nivel de DPP3 determinada con la gravedad, o correlacionar el nivel de DPP3 determinada con el éxito de una terapia, o correlacionar el nivel de DPP3 con una cierta terapia o intervención, o correlacionar el nivel de DPP3 con el manejo del paciente. La materia objeto de la presente invención es un inhibidor de la actividad de DPP3 para usarse en la terapia o intervención en un paciente infectado con un coronavirus.
MX2022011583A 2020-03-16 2021-03-15 Dpp3 en pacientes infectados con coronavirus. MX2022011583A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062990166P 2020-03-16 2020-03-16
EP20163419 2020-03-16
US202063015205P 2020-04-24 2020-04-24
EP20179763.6A EP3922993A1 (en) 2020-06-12 2020-06-12 Dpp3 in patients infected with coronavirus
PCT/EP2021/056579 WO2021185786A1 (en) 2020-03-16 2021-03-15 Dpp3 in patients infected with coronavirus

Publications (1)

Publication Number Publication Date
MX2022011583A true MX2022011583A (es) 2022-10-18

Family

ID=74870834

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011583A MX2022011583A (es) 2020-03-16 2021-03-15 Dpp3 en pacientes infectados con coronavirus.

Country Status (9)

Country Link
US (1) US20230213519A1 (es)
EP (1) EP4121763A1 (es)
JP (1) JP2023518731A (es)
CN (1) CN115769076A (es)
AU (1) AU2021237689A1 (es)
BR (1) BR112022017277A2 (es)
CA (1) CA3171332A1 (es)
MX (1) MX2022011583A (es)
WO (1) WO2021185786A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4552649A3 (en) * 2019-08-30 2025-06-25 4TEEN4 Pharmaceuticals GmbH Therapy guidance and/or therapy monitoring for treatment of shock
JP2025541138A (ja) 2022-12-15 2025-12-18 ４ティーン４ ファーマシューティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング 重篤な患者における肺機能の改善のためのｄｐｐ３阻害剤
EP4687942A1 (en) 2023-03-29 2026-02-11 4TEEN4 Pharmaceuticals GmbH Dpp3 inhibitor for myocardial protection and prevention of myocardial injury in critically ill patients with blood pressure decline
WO2026046947A1 (en) 2024-08-26 2026-03-05 4TEEN4 Pharmaceuticals GmbH Anti-dpp3 antibody directed to and binding to dpp3 for the treatment of shock in extreme-critically ill patients

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
JPS6188884A (ja) 1984-10-04 1986-05-07 Sankyo Co Ltd エンケフアリナ−ゼｂ阻害物質およびその製法
AU634716B2 (en) 1988-08-01 1993-03-04 Ciba Corning Diagnostics Corp. Method for detection of an analyte using acridinium esters and liposomes
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2087997T3 (es) 1990-01-12 1996-08-01 Cell Genesys Inc Generacion de anticuerpos xenogenicos.
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
JPH06508511A (ja) 1990-07-10 1994-09-29 ケンブリッジ　アンティボディー　テクノロジー　リミティド 特異的な結合ペアーの構成員の製造方法
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
JP2005508623A (ja) 2001-08-30 2005-04-07 バイオレクシス ファーマシューティカル コーポレイション 改変されたトランスフェリン融合タンパク質
CA2488558C (en) 2002-06-07 2013-08-20 Dyax Corp. Prevention and reduction of blood loss
WO2005040229A2 (en) 2003-10-24 2005-05-06 Avidia, Inc. Ldl receptor class a and egf domain monomers and multimers
US20100028995A1 (en) 2004-02-23 2010-02-04 Anaphore, Inc. Tetranectin Trimerizing Polypeptides
WO2006032436A2 (en) 2004-09-21 2006-03-30 Nascacell Technologies Ag. Use of microproteins as tryptase inhibitors
ES2373832T3 (es) 2007-12-19 2012-02-09 Affibody Ab Polipéptido derivado de proteína a y capaz de unirse a pdgf.
EP2358746B1 (en) 2008-11-03 2020-09-16 Molecular Partners AG Binding proteins inhibiting the vegf-a receptor interaction
RU2550272C2 (ru) 2009-08-27 2015-05-10 Коваген Аг Новые il-17-связывающие соединения и их медицинское применение
RU2556820C2 (ru) 2009-12-14 2015-07-20 Сцил Протеинс Гмбх Модифицированные убиквитиновые белки со специфической связывающей активностью для экстрадомена "в" фибронектина
US8986951B2 (en) 2010-06-08 2015-03-24 Pieris Ag Tear lipocalin in muteins binding IL-4 R alpha
JP2016508996A (ja) 2013-01-28 2016-03-24 ヌエヴァス オルタナティヴァス ナチュラルズ，エス．エー．ピー．アイ．デ シー．ブイ． 酸化ストレス及び／又は酸化還元不均衡の結果生じる病的状態の全身的治療のための組成物
CH713803B1 (de) 2016-04-21 2023-08-15 4TEEN4 Pharmaceuticals GmbH Verfahren zur Diagnose durch Bestimmung von DPP3, Hemmer der Aktivität von DPP3 und Zusammensetzung mit einem Hemmer.
KR102017217B1 (ko) * 2017-10-19 2019-09-02 주식회사 엔케이맥스 중동호흡기증후군 코로나바이러스에 대한 항체 및 이를 이용한 항체역가 측정방법
MY202502A (en) * 2017-10-25 2024-05-01 4TEEN4 Pharmaceuticals GmbH Dpp3 binder directed to and binding to specific dpp3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stress

Also Published As

Publication number Publication date
AU2021237689A1 (en) 2022-11-03
CA3171332A1 (en) 2021-09-23
US20230213519A1 (en) 2023-07-06
CN115769076A (zh) 2023-03-07
WO2021185786A1 (en) 2021-09-23
BR112022017277A2 (pt) 2022-10-18
JP2023518731A (ja) 2023-05-08
EP4121763A1 (en) 2023-01-25

Similar Documents

Publication Publication Date Title
MX2022011583A (es) Dpp3 en pacientes infectados con coronavirus.
Tayyib et al. Saudi Arabian adult intensive care unit pressure ulcer incidence and risk factors: a prospective cohort study
Frantz et al. Baseline and serial brain natriuretic peptide level predicts 5-year overall survival in patients with pulmonary arterial hypertension: data from the REVEAL registry
Kushnir et al. Assessment of concordance of symptom reflux association tests in ambulatory pH monitoring
Wu et al. Impact of cancer evolution on immune surveillance and checkpoint inhibitor response
AR098155A1 (es) Métodos para diagnosticar y tratar trastornos eosinofílicos
Jones et al. Plantar shear stress in the diabetic foot: a systematic review and meta‐analysis
Wohlfahrt et al. Sulcus fluid bone marker levels and the outcome of surgical treatment of peri‐implantitis
MX2022002432A (es) Orientacion terapeutica y/o monitoreo terapeutico para el tratamiento de choques.
MX2021003164A (es) Perfiles de hidroximetilación de adn circulante en la evaluación de lesiones pancreáticas.
Jones et al. Prevalence of risk factors for foot ulceration in a general haemodialysis population
HK1213892A1 (zh) Tec家族激酶抑制剂疗法的伴随诊断
BR112021026192A2 (pt) Marcador de diagnóstico para câncer pancreático
Gupta et al. The prognostic significance of cardiac structure and function in atrial fibrillation: The ENGAGE AF–TIMI 48 Echocardiographic Substudy
MX2019000003A (es) Adrenomodulina para evaluar la congestión en un individuo con insuficiencia cardiaca aguda.
BR112022019038A2 (pt) Ofatumumab para tratamento de em enquanto mantém a igg sérica
Williams et al. WIfI scoring: a reliable tool for risk stratification in the diabetic foot clinic
Filipowicz-Sosnowska Drug-free remission: the goal of the future in management of patients with rheumatoid arthritis
Marcadis et al. Successful parathyroidectomy guided by intraoperative parathyroid hormone monitoring for primary hyperparathyroidism is preserved in mild and moderate renal insufficiency
Kapur et al. Real world validation of VTE risk models in newly diagnosed multiple myeloma in a community setting
Ha et al. Nationwide evaluation of the validity of the trauma and injury severity score method in korean regional trauma centers using multi-institutional large-scale data
WO2022028917A3 (en) Methods for the determination of the predisposition for a severe or critical course of a covid-19-disease from a mild or moderate course of a covid-19-disease in a subject
Cook et al. A single-centre audit of early warning scores and medical emergency team activation in medical and surgical admissions at Wellington Regional Hospital
Cristina et al. OP0270 LONG-TERM EFFICACY AND SAFETY OF BOSENTAN IN PATIENTS WITH DIGITAL ULCERS RELATED TO SYSTEMIC SCLEROSIS
MX2022011577A (es) Proadrenomedulina o fragmento de la misma en pacientes infectados con coronavirus y tratamientos con aglutinante contra la adrenomedulina.